| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2021―Apr―21 |
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? |
Fedor Simko, Tomas Baka |
| 2 |
[GO] |
2021―Feb―06 |
ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders |
Xi Cao, Li-Ni Song, Jin-Kui Yang |
| 3 |
[GO] |
2021―Jan―29 |
ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease |
Jithin Kuriakose, Augusto C. Montezano, Rhian M. Touyz |
| 4 |
[GO] |
2021―Jan―23 |
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19 |
Maria A Pedrosa, Rita Valenzuela, Pablo Garrido, Carmen M Labandeira, Gemma Navarro, Rafael Franco, et al. (+2) Jose Luis Labandeira-Garcia, Ana I Rodriguez-Perez |
| 5 |
[GO] |
2021―Jan―07 |
Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases |
Ravindra K. Sharma, Jing Li, Suraj Krishnan, Elaine M. Richards, Mohan K. Raizada, Rajesh Mohandas |
| 6 |
[GO] |
2020―Dec―11 |
ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19 |
Michael Bader, Anthony J. Turner, Natalia Alenina |
| 7 |
[GO] |
2020―Dec―09 |
ACE2: from protection of liver disease to propagation of COVID-19 |
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath |
| 8 |
[GO] |
2020―Dec―03 |
Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists |
U. Muscha Steckelings, Colin Sumners |
| 9 |
[GO] |
2020―Nov―25 |
ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19 |
Koichi Yamamoto, Hikari Takeshita, Hiromi Rakugi |
| 10 |
[GO] |
2020―Nov―04 |
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV |
Lizelle Lubbe, Gyles E. Cozier, Delia Oosthuizen, K. Ravi Acharya, Edward D. Sturrock |
| 11 |
[GO] |
2020―Nov―02 |
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery |
Enrique Lores, Jan Wysocki, Daniel Batlle |
| 12 |
[GO] |
2020―Oct―16 |
Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease |
Carlos M. Ferrario, Sarfaraz Ahmad, Leanne Groban |
| 13 |
[GO] |
2020―Sep―29 |
Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19 |
Nigel M. Hooper, Daniel W. Lambert, Anthony J. Turner |
| 14 |
[GO] |
2020―Sep―09 |
Correction: Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission |
|
| 15 |
[GO] |
2020―Sep―01 |
Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera |
Mohamad Aman Jairajpuri, Shoyab Ansari |
| 16 |
[GO] |
2020―Aug―21 |
Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission |
Daniella S. Battagello, Guilherme Dragunas, Marianne O. Klein, Ana L.P. Ayub, Fernando J. Velloso, Ricardo G. Correa |
| 17 |
[GO] |
2020―Aug―04 |
Suppressed anti-inflammatory heat shock response in high-risk COVID-19 patients: lessons from basic research (inclusive bats), light on conceivable therapies |
Thiago Gomes Heck, Mirna Stela Ludwig, Matias Nunes Frizzo, Alberto Antonio Rasia-Filho, Paulo Ivo Homem de Bittencourt |
| 18 |
[GO] |
2020―Jun―16 |
Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy |
Jameel M. Inal |
| 19 |
[GO] |
2020―Jun―16 |
SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure |
Alain R. Thierry, Benoit Roch |
| 20 |
[GO] |
2020―Jun―08 |
Covid-19: the renin-angiotensin system imbalance hypothesis |
Katharina Lanza, Lucas G. Perez, Larissa B. Costa, Thiago M. Cordeiro, Vitria A. Palmeira, Victor T. Ribeiro, Ana Cristina Simões e Silva |
| 21 |
[GO] |
2020―May―22 |
Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs |
Sayeed ur Rehman, Mohammad Tabish |
| 22 |
[GO] |
2020―Apr―07 |
ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19 |
Rhian M. Touyz, Hongliang Li, Christian Delles |
| 23 |
[GO] |
2020―Mar―13 |
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? |
Daniel Batlle, Jan Wysocki, Karla Satchell |
